The extracellular signal regulated kinase (ERK) pathway participates in the control of numerous cellular processes including cell proliferation. As its activation kinetics are critical for to its biological effects, they are tightly regulated. We report that the protein translation factor, eukaryotic translation initiation factor 3, subunit A (eIF3a) binds to SHC and Raf-1, two components of the ERK pathway. The interaction of eIF3a with Raf-1 is increased by arrestin2 expression and transiently decreased by EGF stimulation in a concentration dependent manner. The epidermal growth factor (EGF) induced decrease in Raf-1 -eIF3a association kinetically correlates with the timecourse of ERK activation. eIF3a interferes with Raf-1 activation and eIF3a downregulation by siRNA enhances EGF induced ERK activation, early gene expression and DNA synthesis. Thus, eIF3a serves to negatively modulate the activation of the ERK pathway by EGF.
INTRODUCTION
The ERK pathway is involved in many fundamental cellular processes, including cell proliferation and transformation (3, 7) . The activation sequence of the core components of the pathway is well characterised (24, 31) . The pathway is typically activated by receptor tyrosine kinases, such as the EGF receptor (EGFR), which auto-phosphorylate at their intracellular kinase domains upon ligand binding. These phospho-tyrosines serve as docking sites for adaptor proteins and signal transducers which activate the downstream pathways that mediate the biological effects of the ligands. The ERK pathway is initiated by the translocation of the guanine nucleotide exchange factor (GEF) SOS from the cytosol to the plasma membrane via the adaptor proteins SHC and Grb2 binding to specific phospho-tyrosines at the EGFR. SOS activates Ras, which thereby bringing SOS in the vicinity of Ras proteins at the plasma membrane. SOS activates Ras, which binds to Raf kinases recruiting them to the membrane for activation. Raf activation is a complex process that is still not fully elucidated, and slightly different between the three Raf isoforms A-Raf, Raf and Raf-1. A critical step in Raf-1 activation is the Ras induced dephosphorylation of the inhibitory phospho-S259, which is required for the phosphorylation of the key activating site S338 (9) . Active Raf-1 phosphorylates MEK, which in turn phosphorylates ERK. ERK has >150 substrates in the cytosol and nucleus (37). This large number of substrates enables the pathway to carry out its highly pleiotropic functions, although it is still rather enigmatic as to how specificity in signalling and biological responses is produced. Nevertheless, it is thought that the activation kinetics, spatial organisation, crosstalk and binding to scaffold proteins contribute to the generation of signaling specificity (3, 31) . Thus, although the core pathway is well mapped, identification and analysis of the proteins that modulate these parameters is required in order to understand the functional diversity of the pathway.
We report here the identification of eIF3a as a protein that modulates the activation kinetics of the ERK pathway. eIF3a (also called eIF3, p150, p170) is a component of eIF3, a multi-subunit factor involved in mRNA translation (4, 13, 18) . eIF3 participates in forming the pre-initiation complex and preventing the premature binding of the 40S to the 60S ribosomal subunits (13, 18) . eIF3a can regulate cell cycle progression and proliferation, presumably by controlling the translation of mRNAs encoding the cell cycle inhibitor p27 kip1 and the M2 subunit of ribonucleotide reductase, which is a rate limiting enzyme in DNA synthesis (11, 12) . Similarly, overexpression of certain eIF3 subunits, including eIF3a, can transform NIH 3T3 cells by enhancing global protein synthesis and, in particular, the synthesis of proteins that stimulate proliferation, such as cyclinD1, c-Myc, fibroblast growth factor-2 and ornithine decarboxylase (38). Intriguingly, however, in mammalian cells eIF3a is not deemed essential for the function of eIF3, and not all of eIF3a is associated with ribosomes indicating that it may have functions unrelated to protein translation (28) . Indeed, eIF3a has been reported to bind to actin (26), cytokeratin 7 (21) , and microtubules (16, 29) and the TrkA receptor (23), although the functional consequences of these interactions remain to be ascertained.
We have found that eIF3a can regulate the ERK pathway by binding to SHC and Raf-1.
Critically, the interaction with Raf-1 is enhanced by the signalling scaffold protein arrestin2 and, in doing so, it serves to interferes with Raf-1 activation. Consistent with these observations, the downregulation of eIF3a results in prolonged ERK activation, induction of the nuclear ERK target c-Fos and enhanced proliferation.
MATERIALS AND METHODS
Materials. Doxycycline, monoclonal mouse anti-VSV-G antibody and anti-VSV-G agarose beads were from Sigma-Aldrich (Gillingham, UK), EGF was from Promega (Southampton, UK).
Lipofectamine 2000 transfection reagent was from Invitrogen (Paisley, UK). Protease inhibitor cocktail tablets were from Roche Diagnostics (West Sussex, UK). Polyclonal goat eIF3a antibody, polyclonal rabbit EGFR antibody, monoclonal mouse SOS1 antibody, polyclonal rabbit c-Fos antibody and monoclonal mouse -actin antibody were from Santa Cruz (Heidelberg, Germany). Polyclonal rabbit SHC antibody and monoclonal mouse Ras antibody were from Upstate (Watford, UK). Monoclonal mouse Raf-1 antibody and monoclonal mouse Grb2 antibody were from BD (Oxford, UK). Monoclonal, rabbit -arrestin2 antibody, monoclonal mouse Raf antibody, polyclonal rabbit eIF3a antibody, polyclonal rabbit MEK1/2 antibody, Monoclonal rabbit p44/42 MAPK (ERK1/2) and polyclonal rabbit phospho-p44/42 MAPK (phospho-ERK1/2) antibodies were from Cell Signalling Technology (Hitchin, Hertfordshire, UK). Polyclonal rabbit anti-VSV-G antibody was generated in house.
Generation of stable Flp-In T-REx HEK293 cells inducibly expressing VSV--arrestin2.
VSV-β-arrestin-2 was generated by PCR and inserted into the KpnI-ApaI sites of Co-immunoprecipitation studies -Cells were harvested in co-immunoprecipitation buffer (150mM NaCl, 0.01mM NaPO 4 , 2mM EDTA, 1mM N-ethylmaleimide, 0.5% Triton X-100, and 5% glycerol plus protease inhibitor cocktail tablets) and processed as described above. Instead of elution with VSV peptide samples were resolved by SDS-PAGE and subsequently immunoblotted to detect proteins of interest. Coverslips were mounted with Immu-mount medium (Thermo). Images were collected with an epifluorescent microscope, and BrdU incorporation was quantified. BrdU positive nuclei per total number of nuclei were counted from at least 9 random microscope fields in each experiment. The statistical data come from three independent experiments.
Statistical analysis was done using Student's t-test.
RESULTS
arrestin2 interacts with eIF3a -We identified eIF3a as a arrestin2 associated protein in a proteomic screen, where we used human Flp-In T-REx HEK293 cells engineered to express a doxycycline inducible VSV-tagged arrestin2 in order to identify binding partners of arrestin2. Immunoprecipitation of VSV-arrestin2 co-precipitated eIF3a (Fig. 1A) , and vice versa immunoprecipitation of eIF3a co-precipitated VSV-arrestin2 ( Fig. 1B) . The coprecipitations were strictly dependent on the induction of VSV-arrestin2 expression supporting the specificity of the interaction.
Knockdown of arrestin2 or eIF3a prolongs EGF induced ERK activation -We had
previously reported that arrestin2 mutants that are impaired to dimerize also show a diminished ability to bind to ERK and mediate ERK activation (36). Therefore, we tested the effects of arrestin2 downregulation on ERK activation (Fig. 2) . We stimulated HEK293 cells with EGF and monitored ERK activation by blotting with phospho-specific antibodies detecting the activating phosphorylation sites ( Fig. 2A ). The downregulation of arrestin2 expression slightly augmented and significantly extended ERK activation by EGF (Fig. 2B) .
In order to assess whether eIF3was involved in this effect we downregulated eIF3a and examined ERK activation (Fig. 3A) . Similar to arrestin2, eIF3a knockdown caused a slight increase in the peak of ERK activity and a significant extension of the duration of ERK activation (Fig. 3B) .
These results suggested that eIF3a may be involved in mediating the suppressive effects of arrestin2 on the EGF stimulated ERK pathway.
arrestin2 modulates binding of eIF3a to selected components of the ERK pathway -As eIF3a modulated the activation of ERK in response to EGF, we tested whether eIF3a could interact with components of the ERK pathway. For this purpose we immunoprecipitated endogenous eIF3a and assessed co-precipitation of the EGFR, SHC, Grb2, SOS, Ras, Raf-1, Raf, MEK and ERK (Fig. 4A ). An unrelated, species-matched antibody was used as control.
Specific interactions were observed between eIF3a and SHC, and eIF3a and Raf-1. Interestingly, Raf did not interact with eIF3a suggesting that the interaction is Raf isoform specific. We then examined the influence of arrestin2 on the interaction of eIF3a with SHC and Raf-1 (Fig. 4B ).
While induction of arrestin2 expression had no influence on the interaction between eIF3a and SHC, it enhanced the interaction between eIF3a and Raf-1, suggesting that eIF3a may sequester Raf-1 from EGF activation.
eIF3a binding to Raf-1 is regulated by EGF -
The hypothesis that eIF3a may sequester Raf-1 from EGF mediated activation predicts that EGF stimulation should diminish this interaction.
This was indeed the case (Fig. 5A ). Importantly, EGF caused an early dissociation of Raf-1 from eIF3a and a re-association at later time points, which closely corresponded to the timecourse of ERK activation. In addition, the dissociation of Raf-1 from eIF3a was dependent on the EGF dose ( Fig. 5B) . Again, the progressive disruption of the eIF3a -Raf-1 complex with increasing EGF doses was mirrored by an increase in ERK activation (Fig. 5B) . Interestingly, the fraction of Raf-1 that co-immunoprecipitated with eIF3a was phosphorylated on S259 and stayed phosphorylated on this site after EGF treatment (Fig. 5C ). S259 phosphorylation is inhibitory for
Raf-1 kinase activity and needs to be dephosphorylated for Raf-1 activation to take place (8) .
The dephosphorylation of S259 precedes the phosphorylation of S338 (9), a phosphorylation event which is essential for Raf-1 kinase activation (10) . Raf-1 associated with eIF3a did not become phosphorylated on S338, while S338 phosphorylation was readily observable in lysates in response to EGF treatment (Fig. 5C ). These data further corroborate the hypothesis that eIF3a
binding impedes the activation of Raf-1 and the downstream ERK pathway.
eIF3a regulates nuclear and biological effects of ERK signalling -In response to stimulation
of angiotensin II type 1a receptors arrestins have been shown to function as scaffolds that selectively promote the activation of the ERK pathway in the cytosol, but not in the nucleus (34).
Therefore, we investigated whether eIF3a has a similarly compartmentalized effect on ERK signalling. We first assayed the effect of eIF3a on the induction of c-Fos, an early gene that is a classic transcriptional target of ERK signalling (19) . Down-regulation of eIF3a increased the basal levels c-Fos protein and enhanced the induction of c-Fos protein expression by EGF ( Fig.   6A ) indicating that eIF3a down-regulation also promotes ERK nuclear signalling.
In order to test whether the enhanced ERK signalling enabled by eIF3a down-regulation also has a biological effect, we examined DNA synthesis. While basal DNA synthesis was unchanged, eIF3a down-regulation caused a small, but significant increase in EGF stimulated DNA synthesis. These data confirm that eIF3a has a suppressive effect on signalling through the ERK pathway and the biological outcomes thereof.
DISCUSSION
Our results suggest that arrestin2 can functionally interfere with the activation of the ERK pathway by EGF through enhancing the binding of eIF3a to Raf-1. These data add two new aspects to the regulation of Raf and ERK signalling, namely in revealing novel regulatory roles for arrestin2 and eIF3a.
arrestins1,2 were originally discovered as proteins that terminate GPCR signalling , but have turned out to be multifunctional proteins that play critical roles in coordinating GPCR and EGFR dependent signalling pathways (2, 5, 6, 27) . The relationship mainly has been explored from the role arrestins play in crossregulating EGFR signalling after stimulation of a GPCR. The results suggest a complicated interplay, where arrestins1/2 can have different and antagonistic roles in the regulation of the ERK pathway (1, 14, 15) . Our results suggest that arrestin2 can impede ERK pathway activation by EGF, while down-regulation of arrestin2 enhances ERK activation. This regulation pertains to the duration of ERK signalling rather than to peak activation, and while statistically significant it is quite subtle. These properties may explain why it has not been observed in previous studies.
Differences in spatial and temporal components of ERK activation can lead to profoundly distinct functional effects (20, 25, 30) . Our results also suggest that eIF3a can exert specific regulatory effects on the kinetics of ERK activation through its interaction with arrestin2.
Specifically, this is mediated by arrestin2 binding to eIF3a, which serves to enhances the binding of eIF3a to Raf-1. As arrestin2 can act as scaffold that facilitates the assembly of the Raf-1 -MEK -ERK kinase signalling cascade (22) , and eIF3a also can bind Raf-1, then the enhancing effects of arrestin2 on the eIF3a -Raf-1 interaction may simply be due to the formation of a higher order complex where binding affinities are cooperatively stabilised.
However, while arrestin2 promotes ERK activation (22) , eIF3a interferes with it. Thus, the interactions between Raf-1, arrestin2, and eIF3a may occur in different protein complexes, different subcellular compartments or on different timeframes. Distinguishing between these possibilities is technically extremely challenging and will require future evaluation as and when technologies develop. Nevertheless, our data provide key mechanistic insight in showing that the mechanism of ERK pathway inhibition by eIF3a is the interference with Raf-1 activation, as reflected by a lack of dephosphorylation of the inhibitory residue S259 and failure to phosphorylate S338 in Raf-1. These changes in phosphorylation are Ras dependent and take place at the membrane (8-10), suggesting that eIF3a interference operates at the membrane and not at the endosome level, where arrestin2 is thought to scaffold the Raf-1 -MEK -ERK pathway (22) . Interestingly, eIF3a localisation has been described to include the plasma membrane (26) , which is clearly compatible with a mechanism of interference with Raf-1 activation at the plasma membrane.
In addition to its role in protein translation eIF3a has been suggested to have other functions, especially in cancer, although the findings are contradictory as to whether eIF3a promotes or counteracts cellular transformation (28) . eIF3a is certainly overexpressed in cancers of breast, lung, cervix, oesophagus, stomach and colon (17, 28, 32) . In keeping with a cancer promoting role, overexpression of several eIF3 subunits, including eIF3a, was shown to transform NIH 3T3 fibroblasts (38). However, further studies in cervical, oesophageal and gastric cancer demonstrated that eIF3a overexpression was associated with a better prognosis (28) suggesting that the role of eIF3a in malignancy is more differentiated. Intriguingly, the processes eIF3a is thought to be involved in, such as regulation of the cell cycle and cell differentiation (28) 
